STRATEC reports preliminary figures and adjusts financial guidance
• Sales of € 87.6 million in 9M/2012 (+ 9.3%; 9M/2011: € 80.2 million)
• EBIT margin of 15.3% in 9M/2012 (9M/2011: 18.8%)
• Consolidated net income of € 10.9 million in 9M/2012 (+10.4%; 9M/2011: € 9.8 million)
• Earnings per share of € 0,93 in 9M/2012 (+9,4%; 9M/2011: € 0.85)
• 2012 guidance reduced: Sales of € 120 million to € 125 million / EBIT margin: 14% - 16%
Birkenfeld, October 18, 2012
STRATEC Biomedical AG, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard, TecDAX) today announces its preliminary figures for the period from January 1 to September 30, 2012.
At € 87.6 million, nine-month sales were 9.3% ahead of the previous year’s figure of € 80.2 million. The EBIT margin for the period amounted to 15.3%. Adjusted for a one-off item of € 3.3 million posted in the first quarter of 2012 in connection with the write-down of a development project, sales amounted to € 84.3 million with a corresponding adjusted EBIT margin of 15.9%.
At € 10.9 million, consolidated net income was 10.4% higher than the equivalent figure of € 9.8 million for the first nine months of 2011. If the previous year’s figure is adjusted for a one-off tax back payment of € 1.6 million incurred in 2011, then consolidated net income in 2012 was 5.0% lower than the same period in the previous year (€ 11.4 million).
STRATEC expects to report sales of between € 120 million and € 125 million (previous guidance: € 125 million to € 139 million) for the 2012 financial year ending December 31, 2012. The EBIT margin for the full-year is expected to amount to between 14% and 16% (previous guidance: 17% to 19%).
This lower than expected sales and earnings performance is attributable to weak revenues from maintenance and spare parts and related benefits of scaling effects, market launches being implemented later than expected at our customers, and to a temporarily weaker gross margin for new analyzer systems.
Further details about the business performance in the first nine months of 2012 will be published in the interim report on October 24, 2012.
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, and are a constituent of the Deutsche Börse TecDAX.
Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Phone: +49 7082 7916 190
Fax: +49 7082 7916 999